Latira

Timolol maleate and latanoprost, the active ingredients in Latira, are a beta‑blocker and prostaglandin analog combination presented as eye drops for ocular use. They lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latira is used to manage conditions that involve elevated intra‑ocular pressure within the glaucoma disease family.

Open‑angle glaucoma: reduces intra‑ocular pressure to prevent optic nerve damage. Ocular hypertension: lowers pressure to reduce risk of progression to glaucoma. Post‑surgical ocular hypertension: helps control pressure after ocular surgery.

Common Side Effects: - Blurred vision: transient visual disturbance after instillation. - Eye irritation or burning: mild discomfort at the application site. - Conjunctival hyperemia: redness of the eye. - Increased eyelash growth: longer, thicker lashes. - Darkening of iris: gradual pigmentation change, especially in lighter eyes.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, rash, or difficulty breathing. - Persistent eye pain or inflammation: may indicate uveitis. - Sudden loss of vision: requires immediate medical attention. - Systemic bradycardia: slowed heart rate from systemic absorption. - Respiratory distress: bronchospasm in susceptible individuals.

Before initiating therapy, evaluate patient medical history and monitor intra‑ocular pressure regularly.

Assess cardiovascular status: avoid in patients with severe bradycardia or heart block. Screen for respiratory disease: use cautiously in asthma or COPD. Check for hypersensitivity: discontinue if allergic reaction occurs. Pregnancy and lactation: safety not established; weigh benefits against risks. Store at room temperature: keep in original container, protect from moisture and light.

Latira may interact with other systemic or ocular agents that affect heart rate, blood pressure, or intra‑ocular pressure.

Major Interactions (Avoid): - Systemic beta‑blockers (e.g., propranolol): additive bradycardia. - Sympathomimetic eye drops (e.g., epinephrine): reduced efficacy of timolol. - Other prostaglandin analogs: increased risk of ocular hyperemia.

Moderate Interactions (Monitor Closely):\n- Carbonic anhydrase inhibitors (oral or topical): enhanced IOP‑lowering effect. - Anticholinergic eye drops: possible additive ocular irritation. - NSAID eye drops: may increase risk of corneal complications.